Windlas Biotech announced that the Board of Directors of the Company at its meeting held on 20 May 2024, inter alia, have recommended the final dividend of Rs 5.5 per equity Share (i.e. 110%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Windlas Biotech rose 48.51% to Rs 16.99 crore in the quarter ended March 2024 as against Rs 11.44 crore during the previous quarter ended March 2023. Sales rose 21.73% to Rs 171.29 crore in the quarter ended March 2024 as against Rs 140.71 crore during the previous quarter ended March 2023.For the full year,net profit rose 36.50% to Rs 58.19 crore in the year ended March 2024 as against Rs 42.63 crore during the previous year ended March 2023. Sales rose 22.97% to Rs 630.96 crore in the year ended March 2024 as against Rs 513.08 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales171.29140.71 22 630.96513.08 23 OPM %12.8511.68 -12.3911.74 - PBDT26.1718.61 41 90.5469.40 30 PBT22.6315.04 50 77.0957.04 35 NP16.9911.44 49 58.1942.63 37 Powered by Capital Market - Live News

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 20 May 2024Powered by Capital Market - Live News

Windlas Biotech announced the commissioning of its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards. The Company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. The facility has initiated manufacturing of commercial batches and the company expects to introduce several new products over the course of Financial Year 2025. This milestone marks company`s continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of its business verticals: CDMO, Trade Generics & Institutional, and Exports.Powered by Capital Market - Live News

Net profit of Windlas Biotech rose 64.31% to Rs 15.10 crore in the quarter ended December 2023 as against Rs 9.19 crore during the previous quarter ended December 2022. Sales rose 35.51% to Rs 162.21 crore in the quarter ended December 2023 as against Rs 119.70 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales162.21119.70 36 OPM %12.5411.65 - PBDT23.2015.95 45 PBT19.8112.82 55 NP15.109.19 64 Powered by Capital Market - Live News